Press release
Cutaneous Squamous Cell Carcinoma Pipeline | Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
Cutaneous Squamous Cell Carcinoma Pipeline
To explore more information on the latest breakthroughs in the Cutaneous Squamous Cell Carcinoma Pipeline treatment landscape of the report, click here @ Cutaneous Squamous Cell Carcinoma Pipeline Outlook- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key takeaways from the Cutaneous Squamous Cell Carcinoma Pipeline Report
• DelveInsight's Cutaneous Squamous Cell Carcinoma Pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Cutaneous Squamous Cell Carcinoma treatment.
• The leading Cutaneous Squamous Cell Carcinoma Companies includes Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
• Promising Cutaneous Squamous Cell Carcinoma Pipeline Therapies includes Cemiplimab, IBI318, STP705, Pembrolizumab, PEP005, and others.
• Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
• RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor α-chain (CD25) and IRDye® 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light.
For further information, refer to the detailed Cutaneous Squamous Cell Carcinoma Unmet Needs, Cutaneous Squamous Cell Carcinoma Market Drivers, and Cutaneous Squamous Cell Carcinoma Market Barriers, click here for Cutaneous Squamous Cell Carcinoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cutaneous Squamous Cell Carcinoma Overview
Cutaneous squamous cell carcinoma (SCC) is a common type of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin - the protein that makes up skin, hair and nails. Cutaneous SCC is an invasive disease, referring to cancer cells that have grown beyond the epidermis.
Cutaneous Squamous Cell Carcinoma Emerging Drugs Profile
• HLX 07: Shanghai Henlius Biotech
HLX07 is a bio-better independently developed by Henlius. Adopting the self-developed advanced antibody engineering platform, Henlius re-engineered cetuximab by humanizing its Fab regions and minimizing its glycan contents to generate HLX07 to reduce the immunogenicity and increase the affinity of the product. Pre-clinical studies have shown that HLX07 binds EGFR with similar affinity and had better bioactivity compared to cetuximab. Henlius holds patents of HLX07 in several jurisdictions including China, the United States, the European Union, Australia, and Japan. Moreover, Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
• Opzelura: Incyte Corporation
Opzelura, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
• RM 1995: Rakuten Medical
RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor α-chain (CD25) and IRDye® 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light. Rakuten Medical's preclinical data has suggested that RM-1995 photo immunotherapy treatment can be utilized to specifically deplete intratumoral Tregs, thereby alleviating local Treg-mediated restraint within the tumor microenvironment, rapidly improving the CD8 T cell: Treg ratio, and reinvigorating effector CD8+ T cell responses. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
Request a sample and discover the recent advances in Cutaneous Squamous Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Cutaneous Squamous Cell Carcinoma Treatment Landscape- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cutaneous Squamous Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 45+ key companies which are developing the therapies for Cutaneous Squamous Cell Carcinoma. The companies which have their Cutaneous Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase II include, Incyte Corporation.
Dive deep into rich insights for drugs for Cutaneous Squamous Cell Carcinoma Market Drivers and Cutaneous Squamous Cell Carcinoma Market Barriers, click here @ Cutaneous Squamous Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cutaneous Squamous Cell Carcinoma Pipeline Report
• Coverage- Global
• Cutaneous Squamous Cell Carcinoma Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
• Cutaneous Squamous Cell Carcinoma Pipeline Therapies- Cemiplimab, IBI318, STP705, Pembrolizumab, PEP005, and others.
• Cutaneous Squamous Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Cutaneous Squamous Cell Carcinoma Mergers and acquisitions, Cutaneous Squamous Cell Carcinoma Licensing Activities @ Cutaneous Squamous Cell Carcinoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Cutaneous Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cutaneous Squamous Cell Carcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HLX 07: Shanghai Henlius Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RM 1995: Rakuten Medical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name : Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cutaneous Squamous Cell Carcinoma Key Companies
21. Cutaneous Squamous Cell Carcinoma Key Products
22. Cutaneous Squamous Cell Carcinoma- Unmet Needs
23. Cutaneous Squamous Cell Carcinoma- Market Drivers and Barriers
24. Cutaneous Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Cutaneous Squamous Cell Carcinoma Analyst Views
26. Cutaneous Squamous Cell Carcinoma Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Squamous Cell Carcinoma Pipeline | Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others. here
News-ID: 3072816 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Cutaneous
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Cutaneous Angiosarcoma Market New Product Development & Latest Trends
Introduction
Cutaneous angiosarcoma is a rare and aggressive malignancy that originates from endothelial cells lining blood vessels and lymphatics in the skin. Though it represents a small fraction of soft-tissue sarcomas, its high recurrence rates, metastatic potential, and poor prognosis make it one of the most challenging cancers to manage. The condition most frequently affects elderly patients and is often associated with chronic lymphedema, prior radiation exposure, or immunosuppression.
Traditional management has…
Emerging Trends Influencing The Growth Of The Cutaneous T-Cell Lymphoma Market: …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cutaneous T-Cell Lymphoma Market Size Expected to Be by 2034?
The market for cutaneous T-cell lymphoma has witnessed substantial growth in the past few years. It is projected to rise from a size of $2.54 billion in 2024 to $2.72 billion in 2025, equating to a compound annual…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
